The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings disclosed the funds’ positions on March 31st. We at Insider Monkey have made an extensive database of more than 866 of those established hedge funds and famous value investors’ filings. In this article, we analyze how these elite funds and prominent investors traded Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) based on those filings.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has experienced a decrease in hedge fund interest in recent months. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was in 18 hedge funds’ portfolios at the end of March. The all time high for this statistic is 25. There were 20 hedge funds in our database with VNDA holdings at the end of December. Our calculations also showed that VNDA isn’t among the 30 most popular stocks among hedge funds (click for Q1 rankings).
According to most shareholders, hedge funds are seen as worthless, old financial vehicles of yesteryear. While there are over 8000 funds trading at present, Our experts choose to focus on the masters of this group, approximately 850 funds. Most estimates calculate that this group of people administer most of all hedge funds’ total asset base, and by watching their best investments, Insider Monkey has come up with a number of investment strategies that have historically beaten the broader indices. Insider Monkey’s flagship short hedge fund strategy beat the S&P 500 short ETFs by around 20 percentage points per year since its inception in March 2017. Also, our monthly newsletter’s portfolio of long stock picks returned 206.8% since March 2017 (through May 2021) and beat the S&P 500 Index by more than 115 percentage points. You can download a sample issue of this newsletter on our website .
At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, pet market is growing at a 7% annual rate and is expected to reach $110 billion in 2021. So, we are checking out the 5 best stocks for animal lovers. We go through lists like the 15 best Jim Cramer stocks to identify the next Tesla that will deliver outsized returns. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind let’s take a peek at the fresh hedge fund action regarding Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Do Hedge Funds Think VNDA Is A Good Stock To Buy Now?
At the end of March, a total of 18 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -10% from one quarter earlier. On the other hand, there were a total of 20 hedge funds with a bullish position in VNDA a year ago. So, let’s see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.
According to Insider Monkey’s hedge fund database, Armistice Capital, managed by Steven Boyd, holds the largest position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Armistice Capital has a $57 million position in the stock, comprising 1.3% of its 13F portfolio. Coming in second is Palo Alto Investors, with a $57 million position; the fund has 3.2% of its 13F portfolio invested in the stock. Some other hedge funds and institutional investors that are bullish encompass Renaissance Technologies, D. E. Shaw’s D E Shaw and Israel Englander’s Millennium Management. In terms of the portfolio weights assigned to each position Palo Alto Investors allocated the biggest weight to Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), around 3.25% of its 13F portfolio. Armistice Capital is also relatively very bullish on the stock, setting aside 1.31 percent of its 13F equity portfolio to VNDA.
Seeing as Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has faced declining sentiment from the smart money, it’s easy to see that there is a sect of hedgies that slashed their full holdings by the end of the first quarter. At the top of the heap, Orin Hirschman’s AIGH Investment Partners dumped the biggest stake of all the hedgies watched by Insider Monkey, totaling about $4.6 million in stock, and Steve Cohen’s Point72 Asset Management was right behind this move, as the fund sold off about $2.2 million worth. These bearish behaviors are interesting, as total hedge fund interest dropped by 2 funds by the end of the first quarter.
Let’s now review hedge fund activity in other stocks similar to Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). These stocks are Adaptimmune Therapeutics plc (NASDAQ:ADAP), Tucows Inc. (NYSE:TCX), Byline Bancorp, Inc. (NYSE:BY), Avidity Biosciences, Inc. (NASDAQ:RNA), OptimizeRx Corporation (NASDAQ:OPRX), Allegiance Bancshares, Inc. (NASDAQ:ABTX), and Vasta Platform Limited (NASDAQ:VSTA). This group of stocks’ market values match VNDA’s market value.
|Ticker||No of HFs with positions||Total Value of HF Positions (x1000)||Change in HF Position|
View table here if you experience formatting issues.
As you can see these stocks had an average of 9.3 hedge funds with bullish positions and the average amount invested in these stocks was $107 million. That figure was $207 million in VNDA’s case. Adaptimmune Therapeutics plc (NASDAQ:ADAP) is the most popular stock in this table. On the other hand Vasta Platform Limited (NASDAQ:VSTA) is the least popular one with only 4 bullish hedge fund positions. Compared to these stocks Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is more popular among hedge funds. Our overall hedge fund sentiment score for VNDA is 74.6. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. Our calculations showed that top 5 most popular stocks among hedge funds returned 95.8% in 2019 and 2020, and outperformed the S&P 500 ETF (SPY) by 40 percentage points. These stocks returned 28.5% in 2021 through July 23rd but still managed to beat the market by 10.1 percentage points. Hedge funds were also right about betting on VNDA as the stock returned 30.8% since the end of March (through 7/23) and outperformed the market by an even larger margin. Hedge funds were clearly right about piling into this stock relative to other stocks with similar market capitalizations.
Follow Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Follow Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
- Top 25 Free Games Without Wifi or Internet
- 25 Most Dangerous Countries in 2021
- 10 Best Small-cap Stocks to Buy Now
- 15 Best Gourmet Coffee Brands In The World
Disclosure: None. This article was originally published at Insider Monkey.